Abstract
Adoptive immunotherapy using genetically modified T-cells with a chimeric antigen receptor (CAR) is a promising modality for cancer treatment, because the CAR-grafted T-cells can directly recognize and kill tumor cells, expressing a specific tumor-associated antigen (TAA), in a human leukocyte antigen (HLA)-independent manner. Optimal molecular designs of the CAR and a careful choice of the target TAA are requisite to attain a significant response in CAR-mediated therapy. This review provides a brief overview of the past studies and the present state of CAR research, especially focusing on the development of the CAR protein architecture.
- Received April 4, 2012.
- Revision received May 12, 2012.
- Accepted May 14, 2012.
- Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved